Latest News for: panav

Edit

Panavance Announces New Discovery that Misetionamide Directly Inhibits Oncogenic Transcription Factor c-MYC

Nasdaq Globe Newswire 19 Nov 2024
New finding builds upon previous confirmation of misetionamide’s direct inhibition of NFkB ... .
Edit

Panavance Therapeutics Provides Update on Phase 1 Clinical Trial of Misetionamide in Pancreatic Cancer at ...

Nasdaq Globe Newswire 09 Oct 2024
Misetionamide-gemcitabine combination demonstrates very good safety profile and potential therapeutic benefit in the challenging treatment of pancreatic adenocarcinoma ... .
Edit

Panavance Therapeutics Announces Foundational Publication of Misetionamide (GP-2250) in Ovarian Cancer in the Journal, Cancer Medicine

Nasdaq Globe Newswire 14 Aug 2024
Misetionamide demonstrated significant single agent ...
Edit

Anti-Cancer Drugs Publishes Preclinical Data Demonstrating The Broad Antineoplastic Activity Of Panavance’S Misetionamide (GP-2250)

MENA FN 01 Feb 2024
(MENAFN - GlobeNewsWire - Nasdaq) Misetionamide showed broad antineoplastic activity in 15 different cancer types including multiple human cancer cell lines with no detrimental effect on normal ... .
Edit

International Journal Of Molecular Sciences Publishes Preclinical Data Of Panavance’S Misetionamide (GP-2250) In Melanoma

MENA FN 21 Nov 2023
(MENAFN - GlobeNewsWire - Nasdaq) Misetionamide is effective in targeting and killing BRAF-mutated melanoma cells while preserving normal cellsBRAF-mutated melanoma accounts for approximately 50% of ... .
Edit

Panavance Therapeutics To Participate In The Virtual Investor Summer Spotlight Series

MENA FN 05 Jul 2023
(MENAFN - GlobeNewsWire - Nasdaq) BERWYN, Pa., July 05, 2023 (GLOBE NEWSWIRE) -- panavance therapeutics inc. (–Panavance– or the–Company–), a clinical-stage pharmaceutical company advancing the ... .
Edit

Panavance Therapeutics Announces Publication Of Encouraging Preclinical Data Evaluating Gp-2250 For The Treatment Of Merkel ...

MENA FN 29 Jun 2023
(menafn - globenewswire - nasdaq) data indicate that gp-2250 has anti-neoplastic effects in virus-negative mcc cells as evidenced by tumor cell viability, proliferation and migrationgp-2250 ... .
Edit

Panavance Therapeutics Announces Publication of Encouraging Preclinical Data Evaluating GP-2250 ...

Enid News & Eagle 29 Jun 2023
BERWYN, Pa., June 29, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc ... Greg Bosch, Chairman and CEO of Panavance Therapeutics commented, “We are encouraged by these preclinical findings in this rare, aggressive form of skin cancer.
Edit

Panavance Therapeutics to Present at the Biotechnology Innovation Organization (BIO) International Convention

Nasdaq Globe Newswire 24 May 2023
Live in-person presentation on Tuesday, June 6th at 4.15 PM ET. Live in-person presentation on Tuesday, June 6th at 4.15 PM ET ... .
Edit

Panavance Therapeutics Announces Positive Preclinical Data Demonstrating�GP-2250 Single-Agent and Combination Activity for the Treatment of ...

Nasdaq Globe Newswire 17 Apr 2023
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 ... .
Edit

Panavance Therapeutics Announces Positive Preclinical Data DemonstratingGP-2250 Single-Agent ...

Enid News & Eagle 17 Apr 2023
BERWYN, Pa., April 17, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc ... is now available on the Publications page of the Resource section of the Company’s website ( panavance.com ) ... About Panavance Therapeutics. Panavance Therapeutics Inc.
Edit

Panavance Therapeutics to Present at the BioNJ Annual BioPartnering Conference

Nasdaq Globe Newswire 12 Apr 2023
Live in-person presentation on Tuesday, April 18th at 10.20 AM ET. Live in-person presentation on Tuesday, April 18th at 10.20 AM ET ... .
Edit

Panavance Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer ...

Nasdaq Globe Newswire 20 Mar 2023
BERWYN, Pa., March 20, 2023 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical ...
Edit

Panavance Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

Nasdaq Globe Newswire 05 Jan 2023
Live video webcast on Wednesday, January 18th at 1.00 PM ET. Live video webcast on Wednesday, January 18th at 1.00 PM ET ... .
Edit

Panavance Therapeutics to Participate at the Virtual Investor Innovations in Oncology Spotlight Event

Nasdaq Globe Newswire 05 Dec 2022
Live moderated video webcast roundtable with members of ...

Article Search

tools

Most Viewed

×
×
×
×